Jill Richardson,
Director, Neuroinflammation DPU
After completing a BSc.(Hons) in Biochemistry and a PhD in Developmental Biology at the University of Warwick, U.K., Dr. Richardson was awarded a Fogarty Research Fellowship at the N.I.H, Bethesda, U.S.A. Dr. Richardson joined GlaxoWellcome in 1995 and is currently a Research Director in the Neurosciences Therapeutic Area at GlaxoSmithKline. She has 20 years of leading-edge R&D drug discovery experience in the field of neuroscience, in particular Alzheimer’s disease and multiple sclerosis gained from leadership appointments within Industry and Academia. She is currently leading the GSK Biology Neuroinflammation Discovery Performance Unit based in Shanghai and is leading a project for a molecule in development for multiple sclerosis.
She has over 70 publications that cover molecular, cellular, animal and clinical aspects of neuroscience and in particular neurodegenerative disease. She currently serves as an advisor on the DZNE Senate (Deutsches Zentrum fur Neurodegnerative Erkankungen) and for the NIHR Mental Health Biomedical Research Centre and Dementia Biomedical Research Unit. Dr. Richardson is the EFPIA leader of the 37-partner, 30M Euro IMI PharmaCog project, focused on AD translational research towards increasing the success of drug discovery in AD.
|
|
|
